Hence then, the article about phase 2 data for erleada apalutamide plus androgen deprivation therapy following radical prostatectomy in patients with high risk localized prostate cancer show 100 biochemical free recurrence rate more than two years post surgery was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery )
Also on site :
- Nazanin Zaghari-Ratcliffe joins 100 Iranians urging UK not to get drawn further into Iran war
- Huawei и China Telecom получили награду GSMA GLOMO за вклад в улучшение жизни детей и молодежи
- Global Times: A stable China is fertile ground for foreign businesses to develop